Implanet Enters Exclusive Distribution Partnerships in Australia and New Zealand

By Julie A. Vetalice

Implanet announced the integration of its Jazz Claw device into the Australian Register of Therapeutic Goods and entry into an exclusive partnership with Device Technologies for product distribution in Australia and New Zealand.

CE Marked and FDA cleared, Jazz Claw seeks to provide "autostable" posterior fixation by replacing traditional hook-and-screw fixation systems. The company estimates the Australia vertebral fusion market to be worth US $120MM.

Implanet is participating at the 2017 AAOS meeting in Booth #410.

Sources: Implanet, ORTHOWORLD Inc.

Product Labels: Spinal Fusion

Tags: M&A